Campbell Wilson

Campbell is Senior Pharmaceutical Adviser for Frontier IP. Campbell, who is past Chairman and currently a member of the Board of the UK Pharmaceutical Licensing Group, has worked in the UK pharmaceutical industry for approximately 35 years. The last 17 years of his career were in business development at AstraZeneca, the global research-based biopharmaceutical company, and latterly as Executive Business Development Director within the company’s central Business Development function. He led strategic collaboration and licensing activities at the unit, driving multiple technology and oncology therapy area collaborations and product licensing deals, including high-profile and innovative agreements. Before his involvement in business development, Campbell worked in senior-level scientific roles in cardiovascular drug discovery at AstraZeneca, and earlier at Beecham Pharmaceuticals (now GSK).